Startseite | Sitemap | Impressum | Hilfe
 
Suche:
 
 
   
DGRA INTRANET
 
   
Hier finden Sie interne Informationen für Mitglieder.
Name:
Paßwort:
Paßwort vergessen?
   
GESCHÄFTSADRESSE:
 
   
Adenauerallee 15
D-53111 Bonn

Tel.: 0228 / 368264-6
Fax: 0228 / 368264-7
E-Mail: info@dgra.de
 
STUDIENARBEITEN / MASTER-THESIS
Dr. Kirsten Hiebenthal-Millow (2003) 
Test procedures in the specifications for herbal medicinal products according to CPMP / CVMP-guidelines compared with those for chemically defined medicinal products
Summary

A specification constitutes a list of tests, references to analytical procedures and appropriate acceptance criteria developed by the applicant and approved by the regulatory authority. The tests listed in the specification belong to one of the following five categories: definition / description, test of identity, test of purity, assay and other tests. Different CPMP/CVMP-guidelines are published that give guidance on how to establish which tests should be included in the specification of herbal medicinal products and chemically defined medicinal products. In this masterthesis it is summarised and compared which test parameters have to be included into a specification of a herbal drug, herbal preparation and herbal medicinal product on the one side and starting material, drug substance and drug product of chemically defined medicinal products one the other side according to these CPMP/CVMP-guidelines.

The principle difference between herbal medicinal products and chemically defined medicinal products is that the active ingredient of the herbal medicinal product constitutes a mixture of a variety of substances. As a consequence different test parameters have to be included into the specification as to test a material of complex composition calls for other tests than defining, identifying, quantifying etc a single substance.

Altogether the comparison yields that the definition and tests on identity are more significant for herbal drugs, herbal preparation and herbal medicinal products, whereas the test on purity and assay is of more significance for starting material, drug substance and drug product of chemically defined medicinal products.

Pages: 33

 
« zurück
 
nach oben drucken weiterempfehlen
 
Studiengang (M.D.R.A.)
Abschluß: Master of Drug
Regulatory Affairs
mehr Informationen »
DGRA-Fortbildungen:
DGRA Schools:

21. - 22. März 2012
DGRA-School | Zulassung USA

DGRA Workshops:

06. März 2012
Variations

28. - 29. August 2012
Update Workshop

27. November 2012
Therapeutische Vaccine

Jahreskongresse:

30. - 31. Mai 2012
DGRA-Jahreskongress 2012

mehr Fortbildungen »
Job-Börse:
Angebot vom 12.01.2012
Manager Pharmacovigilance and Medical Affairs (m/w)

Angebot vom 09.12.2011
Labeling-Manager im Bereich Zulassung/ Qualität (m/w)

mehr Stellenangebote »
© 2011, DGRA e.V.
Letzte Aktualisierung am:
Donnerstag, 07.12.2006